Journal of the American Heart Association,
Journal Year:
2019,
Volume and Issue:
8(19)
Published: Sept. 30, 2019
Background
Whether
marine
omega‐3
supplementation
is
associated
with
reduction
in
risk
of
cardiovascular
disease
(CVD)
remains
controversial.
Methods
and
Results
This
meta‐analysis
included
study‐level
data
from
13
trials.
The
outcomes
interest
myocardial
infarction,
coronary
heart
(CHD)
death,
total
CHD,
stroke,
CVD
CVD,
major
vascular
events.
unadjusted
rate
ratios
were
calculated
using
a
fixed‐effect
meta‐analysis.
A
meta‐regression
was
conducted
to
estimate
the
dose–response
relationship
between
dosage
each
prespecified
outcome.
During
mean
treatment
duration
5.0
years,
3838
infarctions,
3008
CHD
deaths,
8435
events,
2683
strokes,
5017
15
759
16
478
events
documented.
In
analysis
excluding
REDUCE‐IT
(Reduction
Cardiovascular
Events
Icosapent
Ethyl‐Intervention
Trial),
significantly
lower
infarction
(rate
ratio
[RR]
[95%
CI]:
0.92
[0.86,
0.99];
P
=0.020),
death
(RR
0.98];
=0.014),
0.95
[0.91,
=0.008),
0.93
[0.88,
=0.013),
0.97
[0.94,
=0.015).
Inverse
associations
for
all
strengthened
after
including
while
introducing
statistically
significant
heterogeneity.
Statistically
linear
relationships
found
analyses
without
REDUCE‐IT.
Conclusions
Marine
lowers
even
exclusion
Risk
reductions
appeared
be
linearly
related
dose.
Arquivos Brasileiros de Cardiologia,
Journal Year:
2019,
Volume and Issue:
unknown
Published: Jan. 1, 2019
Introducao
A
doenca
cardiovascular
(DCV)
e
a
principal
causa
de
morte
no
Brasil
mundo,
determinando
aumento
da
morbidade
incapacidade
ajustadas
pelos
anos
vida.
Embora
as
taxas
mortalidade
disability-adjusted
life
year
(DALY)
padronizadas
por
idade
estejam
diminuindo
Brasil,
possivelmente
como
resultado
politicas
saude
bem-sucedidas,
o
numero
total
destas
esta
aumentando
principalmente
devido
ao
envelhecimento
adoecimento
populacao.
presenca
dos
fatores
risco
classicos
(hipertensao,
dislipidemia,
obesidade,
sedentarismo,
tabagismo,
diabetes
[...]
International Journal of Molecular Sciences,
Journal Year:
2018,
Volume and Issue:
19(11), P. 3285 - 3285
Published: Oct. 23, 2018
Lipid
and
immune
pathways
are
crucial
in
the
pathophysiology
of
metabolic
cardiovascular
disease.
Arachidonic
acid
(AA)
its
derivatives
link
nutrient
metabolism
to
immunity
inflammation,
thus
holding
a
key
role
emergence
progression
frequent
diseases
such
as
obesity,
diabetes,
non-alcoholic
fatty
liver
disease,
We
herein
present
synopsis
AA
human
health,
tissue
homeostasis,
immunity,
explore
metabolome
diverse
pathophysiological
conditions
diseases.
Aging Cell,
Journal Year:
2019,
Volume and Issue:
18(6)
Published: Sept. 27, 2019
Abstract
An
emerging
body
of
data
suggests
that
lipid
metabolism
has
an
important
role
to
play
in
the
aging
process.
Indeed,
a
plethora
dietary,
pharmacological,
genetic,
and
surgical
lipid‐related
interventions
extend
lifespan
nematodes,
fruit
flies,
mice,
rats.
For
example,
impairment
genes
involved
ceramide
sphingolipid
synthesis
extends
both
worms
flies.
The
overexpression
fatty
acid
amide
hydrolase
or
lysosomal
lipase
prolongs
life
Caenorhabditis
elegans
,
while
diacylglycerol
enhances
longevity
C.
Drosophila
melanogaster
.
removal
adipose
tissue
rats,
increased
expression
apolipoprotein
D
survival
flies
mice.
Mouse
can
be
additionally
extended
by
genetic
deletion
acyltransferase
1,
treatment
with
steroid
17‐α‐estradiol,
ketogenic
diet.
Moreover,
phospholipase
A2
receptor
improves
various
healthspan
parameters
progeria
mouse
model.
Genome‐wide
association
studies
have
found
several
variants
associated
human
aging.
epsilon
2
4
alleles
E
are
extreme
late‐onset
neurodegenerative
disease,
respectively.
In
humans,
blood
triglyceride
levels
tend
increase,
lysophosphatidylcholine
decrease
age.
Specific
phospholipid
profiles
also
been
shown
change
age
exceptional
longevity.
These
suggest
may
improve
lipids
likely
represent
rich
source
biomarkers.
Journal of the American Heart Association,
Journal Year:
2019,
Volume and Issue:
8(19)
Published: Sept. 30, 2019
Background
Whether
marine
omega‐3
supplementation
is
associated
with
reduction
in
risk
of
cardiovascular
disease
(CVD)
remains
controversial.
Methods
and
Results
This
meta‐analysis
included
study‐level
data
from
13
trials.
The
outcomes
interest
myocardial
infarction,
coronary
heart
(CHD)
death,
total
CHD,
stroke,
CVD
CVD,
major
vascular
events.
unadjusted
rate
ratios
were
calculated
using
a
fixed‐effect
meta‐analysis.
A
meta‐regression
was
conducted
to
estimate
the
dose–response
relationship
between
dosage
each
prespecified
outcome.
During
mean
treatment
duration
5.0
years,
3838
infarctions,
3008
CHD
deaths,
8435
events,
2683
strokes,
5017
15
759
16
478
events
documented.
In
analysis
excluding
REDUCE‐IT
(Reduction
Cardiovascular
Events
Icosapent
Ethyl‐Intervention
Trial),
significantly
lower
infarction
(rate
ratio
[RR]
[95%
CI]:
0.92
[0.86,
0.99];
P
=0.020),
death
(RR
0.98];
=0.014),
0.95
[0.91,
=0.008),
0.93
[0.88,
=0.013),
0.97
[0.94,
=0.015).
Inverse
associations
for
all
strengthened
after
including
while
introducing
statistically
significant
heterogeneity.
Statistically
linear
relationships
found
analyses
without
REDUCE‐IT.
Conclusions
Marine
lowers
even
exclusion
Risk
reductions
appeared
be
linearly
related
dose.
